Infantile hemangiomas are the most frequent vascular tumours in children, affecting up to 12% of babies in their first year. Infantile hemangioma appears in the first few weeks of life, grows in size over 3 to 6 months, and then gradually fades over 3 to 7 years. Three-quarters of these hemangiomas are lobular and have no abnormalities associated with them. Segmental hemangiomas, on the other hand, have been linked to developmental problems (PHACES and PELVIS/SACRAL syndromes). The vast majority of infantile hemangiomas do not necessitate therapy. Treatment options include oral propranolol, topical timolol, and oral corticosteroids in 10 to 15% of patients. Hemorrhage that is not responding to treatment, approaching ulceration in places where serious complications could occur, interference with essential structures, life- or function-threatening consequences, and significant disfigurement are all indications for aggressive intervention. Treatment should be tailored to the individual. size, pace of growth, form, quantity, and location of the lesion (s), current or potential consequences, treatment benefits and side effects, patient age, parental worry, and physician comfort level with various treatment choices

Author (s) Details

Assistant Professor Dr. Alper Özkılıç
Biruni University Department of Pediatrics, İstanbul, Turkey.

Assistant Professor Dr. Hüseyin Avni Solgun
SBU Basaksehir Cam and Sakura Hospital/Pediatric Hematology and Oncology, İstanbul, Turkey.


View Book :- https://stm.bookpi.org/HMMS-V16/article/view/2387